ICON Public Limited Company (ICLR)
- Previous Close
324.82 - Open
322.80 - Bid 320.83 x 100
- Ask 322.10 x 100
- Day's Range
317.18 - 330.91 - 52 Week Range
216.78 - 344.77 - Volume
276,700 - Avg. Volume
515,682 - Market Cap (intraday)
26.586B - Beta (5Y Monthly) 1.18
- PE Ratio (TTM)
38.97 - EPS (TTM)
8.25 - Earnings Date Jul 24, 2024 - Aug 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
365.07
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.
www.iconplc.com41,150
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: ICLR
Performance Overview: ICLR
Trailing total returns as of 6/3/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ICLR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ICLR
Valuation Measures
Market Cap
26.86B
Enterprise Value
30.10B
Trailing P/E
39.42
Forward P/E
21.69
PEG Ratio (5yr expected)
2.05
Price/Sales (ttm)
3.27
Price/Book (mrq)
2.85
Enterprise Value/Revenue
3.66
Enterprise Value/EBITDA
18.87
Financial Highlights
Profitability and Income Statement
Profit Margin
8.30%
Return on Assets (ttm)
4.01%
Return on Equity (ttm)
7.55%
Revenue (ttm)
8.23B
Net Income Avi to Common (ttm)
683.12M
Diluted EPS (ttm)
8.25
Balance Sheet and Cash Flow
Total Cash (mrq)
400.94M
Total Debt/Equity (mrq)
39.03%
Levered Free Cash Flow (ttm)
1.11B